AiCuris Anti-infective Cures AG (AiCuris) is a German biopharmaceutical company based in Wuppertal focused on the discovery and development of anti-infective therapies. The company concentrates on innovative antivirals targeting herpesviruses and other opportunistic infections, aiming to address high unmet medical needs in immunocompromised patients, including transplant recipients.
AiCuris is known for discovering letermovir (marketed as Prevymis for cytomegalovirus prophylaxis), which it out-licensed for global commercialization. Its pipeline includes clinical-stage candidates such as pritelivir, a helicase–primase inhibitor for difficult-to-treat herpes simplex virus infections. Operating as an Aktiengesellschaft, AiCuris leverages deep virology expertise and translational development to advance new treatment options through internal R&D and collaborations.
